Resumen de acción D05 Deciphera Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla medicamentos para mejorar la vida de los pacientes con cáncer abordando los mecanismos clave de resistencia a los medicamentos que limitan la tasa y la durabilidad de la respuesta a las terapias contra el cáncer existentes en los Estados Unidos e internacionalmente. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Deciphera Pharmaceuticals, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Deciphera Pharmaceuticals Precios históricos de las acciones Precio actual de la acción US$23.60 Máximo en las últimas 52 semanas US$23.80 Mínimo de 52 semanas US$9.51 Beta 0.18 Cambio en 1 mes 0% Variación en 3 meses 60.49% Cambio de 1 año 84.66% Variación en 3 años -19.18% Variación en 5 años 11.58% Variación desde la OPV 40.22%
Noticias y actualizaciones recientes
Deciphera Pharmaceuticals, Inc. Files Form 15 Jun 22 Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet Jun 05
First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023) May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 27 Ver más actualizaciones
Deciphera Pharmaceuticals, Inc. Files Form 15 Jun 22 Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet Jun 05
First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023) May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 27
Full year 2023 earnings released: US$2.29 loss per share (vs US$2.37 loss in FY 2022) Feb 07
Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024 Feb 02
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 Jan 09
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Jan 05
President recently sold €437k worth of stock Dec 17
Senior VP & Chief Commercial Officer recently sold €205k worth of stock Dec 04
President recently sold €244k worth of stock Nov 02
President recently sold €244k worth of stock Nov 02
Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Oct 31
Third quarter 2023 earnings released: US$0.58 loss per share (vs US$0.55 loss in 3Q 2022) Oct 31
New minor risk - Share price stability Oct 10
Second quarter 2023 earnings released: US$0.57 loss per share (vs US$0.60 loss in 2Q 2022) Aug 10
Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023 Aug 05
Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Now 22% undervalued after recent price drop Jun 15
Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting May 26
Now 22% undervalued after recent price drop May 23
Independent Director recently bought €139k worth of stock May 15
First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.80 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$2.37 loss per share (vs US$5.16 loss in FY 2021) Feb 08
Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Feb 01
Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Jan 25
Now 21% undervalued Jan 11
Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 05 Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.37 loss in 3Q 2021) Nov 04
Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022 Sep 12
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022 Sep 11
Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology Aug 11
Second quarter 2022 earnings released: US$0.60 loss per share (vs US$1.22 loss in 2Q 2021) Aug 05
Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer Jun 17
First quarter 2022 earnings released: US$0.80 loss per share (vs US$1.06 loss in 1Q 2021) May 05
Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022 May 03
Insufficient new directors Apr 27
Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting Apr 13
Insufficient new directors Mar 02
Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022 Feb 02
Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Jan 25
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Dec 22
Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor Nov 24
Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020) Nov 03
Executive VP & Chief Medical Officer recently sold €76k worth of stock Oct 09 Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Second quarter 2021 earnings released: US$1.22 loss per share (vs US$1.20 loss in 2Q 2020) Aug 05
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene Jul 01
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 05
First quarter 2021 earnings released: US$1.06 loss per share (vs US$1.36 loss in 1Q 2020) May 06
New 90-day low: €34.40 Feb 27
Full year 2020 earnings released: US$4.78 loss per share (vs US$4.49 loss in FY 2019) Feb 11
Revenue beats expectations Feb 11
Deciphera Pharmaceuticals, Inc. Announces Appointment of Margarida Duarte as Senior Vice President, Head of International Feb 10
Deciphera Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 09, 2021 Feb 03
New 90-day low: €38.20 Jan 23
New 90-day low: €43.00 Jan 07
Deciphera Pharmaceuticals, Inc. Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor Dec 01
New 90-day high: €54.50 Nov 13 Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Revenue beats expectations Nov 07
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize Qinlock (Ripretinib) Nov 07
Specialised Therapeutics Asia Signs an Agreement with Deciphera Pharmaceuticals, Inc. to Commercialise the Switch-Control Tyrosine Kinase Inhibitor QINLOCK (ripretinib) Nov 06
Deciphera Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 29
New 90-day high: €52.50 Oct 24
New 90-day high: €48.20 Oct 08
Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology Virtual Congress 2020 Sep 19
Deciphera Pharmaceuticals, Inc. Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Sep 18
New 90-day low - €36.80 Aug 20
Deciphera Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 31
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from Russell Microcap Index Jul 02 Rentabilidad de los accionistas D05 DE Biotechs Mercado DE 7D 1.7% 1.1% -0.02% 1Y 84.7% -3.7% 15.1%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: D05 superó a la industria German Biotechs, que obtuvo un rendimiento del -3.7% el año pasado.
Rentabilidad vs. Mercado: D05 superó al mercado German, que obtuvo un rendimiento del 15.1% el año pasado.
Volatilidad de los precios Is D05's price volatile compared to industry and market? D05 volatility D05 Average Weekly Movement 22.0% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: El precio de las acciones de D05 ha sido volátil durante los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de D05 ha aumentado de 12% a 22% en el último año.
Acerca de la empresa Deciphera Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla medicamentos para mejorar la vida de los pacientes con cáncer abordando los mecanismos clave de resistencia a los medicamentos que limitan la tasa y la durabilidad de la respuesta a las terapias contra el cáncer existentes en los Estados Unidos e internacionalmente. Su principal candidato a fármaco es QINLOCK, utilizado para el tratamiento de tumores del estroma gastrointestinal (GIST), así como en el estudio de fase 3 INTRIGUE para tratar GIST de segunda línea. La empresa también está desarrollando vimseltinib, un potente inhibidor de la cinasa de control conmutado del receptor del factor estimulante de colonias 1 (CSF1R), de administración oral y altamente selectivo, para el tratamiento del tumor tenosinovial de células gigantes (TGCT); y DCC-3116 para tratar cánceres mutantes RAS/RAF, que se encuentra en fase preclínica.
Mostrar más Resumen de fundamentos de Deciphera Pharmaceuticals, Inc. ¿Cómo se comparan los beneficios e ingresos de Deciphera Pharmaceuticals con su capitalización de mercado? Estadísticas fundamentales de D05 Capitalización bursátil €2.06b Beneficios(TTM ) -€177.33m Ingresos (TTM ) €162.89m
12.7x Ratio precio-ventas (PS)
-11.6x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de D05 Ingresos US$174.91m Coste de los ingresos US$242.52m Beneficio bruto -US$67.61m Otros gastos US$122.80m Beneficios -US$190.42m
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -2.20 Margen bruto -38.66% Margen de beneficio neto -108.87% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado D05 a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/06/11 15:22 Precio de las acciones al final del día 2024/06/11 00:00 Beneficios 2024/03/31 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github .
Fuentes analistas Deciphera Pharmaceuticals, Inc. está cubierta por 17 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Madhu Kumar B. Riley Securities, Inc. Arlinda Lee Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co.
Mostrar 14 más analistas 
